<NEWS>
<?xml version="1.0"?>
<DOCS>
<DOC>
<DOCNO>251</DOCNO>
<PROFILE>D.H.E 45-FDA (Dihydroergotamine)
</PROFILE>

<HEADLINE>dihydroergotamine mesylate, USP 1 mg, methanesulfonic acid/sodium hydroxide, qs to pH 3.6 ± 0. 4 6.1 % by vol. glycerin, UP 15% by wt. water for injection, USP , qs to 1 ml.</HEADLINE>

<TEXT>
D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>



<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>



<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>



<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>



<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>



<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>



<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>



<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>



<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>



<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>



<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>



<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>



<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>


<DOC>
<DOCNO>252</DOCNO>
<PROFILE>Dacarbazine(Dtic - FDA Dome)
</PROFILE>

<HEADLINE>
100 mg of dacarbazine, or 200 mg of dacarbazine (the active ingredient), anhydrous citric acid and mannitol</HEADLINE>

<TEXT>
DTlC-Dome is indicated in the treatment of metastatic malignant melanoma. In addition, DTlC-Dome is also indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents.ns.</TEXT>

</DOC>



</DOCS>
</NEWS>